Diaceutics PLC (LSE:DXRX) — Market Cap & Net Worth
Market Cap & Net Worth: Diaceutics PLC (DXRX)
Diaceutics PLC (LSE:DXRX) has a market capitalization of $1.48 Million (GBX12.14 Billion) as of August 1, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30271 globally and #740 in its home market, demonstrating a 11.67% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Diaceutics PLC's stock price GBX143.50 by its total outstanding shares 84629450 (84.63 Million). See Diaceutics PLC (DXRX) capital reinvestment to understand how much of operating cash flow is reinvested back into capital assets.
Diaceutics PLC Market Cap History: 2019 to 2026
Diaceutics PLC's market capitalization history from 2019 to 2026. Data shows growth from $1.05 Million to $1.48 Million (5.68% CAGR).
Index Memberships
Diaceutics PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$906.99 Million | 0.16% | #126 of 722 |
Weight: Diaceutics PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Diaceutics PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Diaceutics PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.04x
Diaceutics PLC's market cap is 0.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $1.05 Million | $13.44 Million | $398.00K | 0.08x | 2.64x |
| 2020 | $1.37 Million | $12.70 Million | $263.00K | 0.11x | 5.23x |
| 2021 | $1.05 Million | $13.94 Million | $561.00K | 0.08x | 1.87x |
| 2022 | $777.42K | $19.50 Million | $724.00K | 0.04x | 1.07x |
| 2023 | $895.84K | $23.70 Million | -$1.75 Million | 0.04x | N/A |
| 2024 | $1.29 Million | $32.16 Million | -$1.70 Million | 0.04x | N/A |
Competitor Companies of DXRX by Market Capitalization
Companies near Diaceutics PLC in the global market cap rankings as of August 1, 2026.
Key companies related to Diaceutics PLC by market ranking:
- Veeva Systems Inc Class A (NYSE:VEEV): Ranked #980 globally with a market cap of $27.24 Billion USD.
- Pro Medicus Ltd (AU:PME): Ranked #1931 globally with a market cap of $11.99 Billion USD ( AU$16.95 Billion AUD).
- BrightSpring Health Services, Inc. Common Stock (NASDAQ:BTSG): Ranked #2123 globally with a market cap of $10.63 Billion USD.
- Tempus AI, Inc. Class A Common Stock (NASDAQ:TEM): Ranked #2675 globally with a market cap of $7.62 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #980 | Veeva Systems Inc Class A | NYSE:VEEV | $27.24 Billion | $203.78 |
| #1931 | Pro Medicus Ltd | AU:PME | $11.99 Billion | AU$162.21 |
| #2123 | BrightSpring Health Services, Inc. Common Stock | NASDAQ:BTSG | $10.63 Billion | $59.71 |
| #2675 | Tempus AI, Inc. Class A Common Stock | NASDAQ:TEM | $7.62 Billion | $43.87 |
Diaceutics PLC Historical Marketcap From 2019 to 2026
Between 2019 and today, Diaceutics PLC's market cap moved from $1.05 Million to $ 1.48 Million, with a yearly change of 5.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX1.48 Million | +12.11% |
| 2025 | GBX1.32 Million | +1.99% |
| 2024 | GBX1.29 Million | +44.25% |
| 2023 | GBX895.84K | +15.23% |
| 2022 | GBX777.42K | -25.98% |
| 2021 | GBX1.05 Million | -23.60% |
| 2020 | GBX1.37 Million | +30.88% |
| 2019 | GBX1.05 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Diaceutics PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.48 Million USD |
| MoneyControl | $1.48 Million USD |
| MarketWatch | $1.48 Million USD |
| marketcap.company | $1.48 Million USD |
| Reuters | $1.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Diaceutics PLC
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, which d… Read more